FLGT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fulgent Genetics Inc (FLGT) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has shown a positive price movement recently and has an upcoming earnings report, the financial performance indicates declining profitability, and hedge funds are selling heavily. The lack of strong trading signals and mixed catalysts suggest holding off on purchasing until clearer positive trends emerge.
The stock is showing positive momentum with a 5.09% regular market increase and a 2.26% post-market increase. The MACD is positive and expanding, indicating bullish momentum. However, RSI at 75.556 is in the neutral zone, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its resistance level (R2: 25.126), which could limit further short-term upside.
The company has consistently beaten EPS estimates 100% of the time and revenue estimates 75% over the past two years.
Revenue is expected to increase by 12.3% YoY in the upcoming Q4 earnings report.
Gross margin improved by 15.32% YoY in Q3 2025.
Hedge funds are heavily selling, with a 169.46% increase in selling activity over the last quarter.
Net income and EPS have significantly declined YoY (-54.89% and -56.25%, respectively).
The upcoming earnings report projects a 25% YoY decline in EPS, which may weigh on investor sentiment.
In Q3 2025, revenue increased by 17.18% YoY to $84.07M, but net income dropped by 54.89% YoY to -$6.61M. EPS also declined by 56.25% YoY to -$0.21. Gross margin improved to 39.83%, up 15.32% YoY, indicating better operational efficiency despite declining profitability.
No recent analyst rating or price target changes are available for FLGT. Wall Street sentiment appears mixed, with no clear consensus on the stock's future direction.
